NO2768984T3 - - Google Patents

Info

Publication number: NO2768984T3
Authority: NO; Norway

Application number

NO12841612A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2012-10-19

Publication date

2018-06-09

2012-10-19 Application filed filed Critical

2018-06-09 Publication of NO2768984T3 publication Critical patent/NO2768984T3/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)
Organic Insulating Materials (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

NO12841612A 2015-11-12 2012-10-19 NO2768984T3 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562254375P	2015-11-12	2015-11-12

Publications (1)

Publication Number	Publication Date
NO2768984T3 true NO2768984T3 (no)	2018-06-09

Family

ID=57348648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO12841612A NO2768984T3 (no)	2015-11-12	2012-10-19

Country Status (36)

Country	Link
US (2)	US10544211B2 (no)
EP (2)	EP3266798A3 (no)
JP (2)	JP6962915B2 (no)
KR (2)	KR20240029115A (no)
CN (1)	CN108473563B (no)
AU (2)	AU2016352943B2 (no)
BR (1)	BR112018009714A8 (no)
CA (2)	CA3005085A1 (no)
CL (1)	CL2018001291A1 (no)
CO (1)	CO2018005915A2 (no)
CR (1)	CR20180311A (no)
CY (1)	CY1120303T1 (no)
DK (1)	DK3191511T3 (no)
DO (1)	DOP2018000122A (no)
EC (1)	ECSP18042569A (no)
ES (1)	ES2662418T3 (no)
GT (1)	GT201800095A (no)
HK (1)	HK1248716A1 (no)
HR (1)	HRP20171949T1 (no)
HU (1)	HUE035805T2 (no)
IL (2)	IL259269B2 (no)
LT (1)	LT3191511T (no)
MA (1)	MA41653A (no)
MD (1)	MD3191511T2 (no)
ME (1)	ME02954B (no)
MX (1)	MX2018005992A (no)
NO (1)	NO2768984T3 (no)
PE (1)	PE20181317A1 (no)
PH (1)	PH12018501025A1 (no)
PL (1)	PL3191511T3 (no)
PT (1)	PT3191511T (no)
RS (1)	RS56676B1 (no)
SG (1)	SG11201803975SA (no)
SI (1)	SI3191511T1 (no)
TN (1)	TN2018000159A1 (no)
WO (1)	WO2017081320A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR102246924B1 (ko)	2011-06-23	2021-04-30	아블린쓰 엔.브이.	면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
HUE058008T2 (hu)	2014-05-16	2022-06-28	Ablynx Nv	Immunglobulin variábilis domének
NO2768984T3 (no) *	2015-11-12	2018-06-09
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
BR112022010231A2 (pt)	2019-12-06	2022-09-06	Ablynx Nv	Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l
BR112022009799A2 (pt)	2019-12-06	2022-08-16	Ablynx Nv	Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23
CN112300289B (zh) *	2019-12-30	2022-06-10	中国药科大学	RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
EP4263602A1 (en)	2020-12-18	2023-10-25	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
WO2024097571A1 (en) *	2022-11-04	2024-05-10	St. Jude Children's Research Hospital, Inc.	Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
WO2024133935A1 (en)	2022-12-23	2024-06-27	Ablynx Nv	Protein-based conjugation carriers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2338791T3 (es)	1992-08-21	2010-05-12	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CN1203178C (zh)	1997-10-27	2005-05-25	尤尼利弗公司	多价抗原结合蛋白
BR9907950A (pt)	1998-02-19	2001-12-18	Xcyte Therapies Inc	Composições e processos para regulagem deativação de linfócitos
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20060228355A1 (en)	2003-11-07	2006-10-12	Toon Laeremans	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP2284192A3 (en) *	2002-11-08	2011-07-20	Ablynx N.V.	Camelidae antibodies for sublingual administration
MXPA05006043A (es)	2003-01-10	2006-01-30	Ablynx Nv	Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
EP2221317A3 (en)	2003-06-30	2011-07-27	Domantis Limited	PEGylated single domain antibodies (dAb)
JP5113523B2 (ja)	2004-10-13	2013-01-09	アブリンクスナームローゼフェンノートシャップ	アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
WO2006059108A2 (en)	2004-12-02	2006-06-08	Domantis Limited	ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
DK1888641T3 (da) *	2005-05-18	2012-04-23	Ablynx Nv	Serumalbuminbindende proteiner
EP3415535B1 (en)	2005-05-20	2020-12-09	Ablynx N.V.	Improved nanobodies tm for the treatment of aggregation-mediated disorders
DE102005023617A1 (de) *	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
EP1948206B1 (en)	2005-08-30	2017-03-01	Intrexon Actobiotics NV	Anti-tnf alpha producing lactic acid bacteria for the treatment of inflammatory bowel disease
CA2629850A1 (en)	2005-12-01	2007-06-07	Domantis Limited	Competitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007063308A2 (en)	2005-12-01	2007-06-07	Domantis Limited	Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	Chaine de reception par satellite
CA2640066A1 (en)	2006-01-24	2007-08-02	Roland Beckmann	Fusion proteins that contain natural junctions
US8629244B2 (en)	2006-08-18	2014-01-14	Ablynx N.V.	Interleukin-6 receptor binding polypeptides
EP2097449A1 (en)	2006-12-05	2009-09-09	Ablynx N.V.	Peptides capable of binding to serum proteins
RU2481355C2 (ru)	2007-05-24	2013-05-10	Аблинкс Н.В.	Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
EP2215125A1 (en)	2007-11-27	2010-08-11	Ablynx N.V.	Method for obtaining polypeptide constructs comprising two or more single domain antibodies
DE102008023620A1 (de)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
KR20110020825A (ko)	2008-05-16	2011-03-03	아블린쓰 엔.브이.	Ｃｘｃｒ4 및 다른 ｇｐｃｒ에 대해 유도된 아미노산 서열 및 이를 포함하는 화합물
KR20110119806A (ko) *	2009-02-19	2011-11-02	글락소 그룹 리미티드	개선된 항ｔｎｆｒ1 폴리펩티드，항체 가변 도메인 및 길항제
AU2010233658B2 (en)	2009-04-10	2013-11-28	Ablynx Nv	Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EP2454285A2 (en)	2009-07-16	2012-05-23	Glaxo Group Limited	Improved anti-serum albumin binding single variable domains
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
US20150158948A9 (en)	2011-03-28	2015-06-11	Francis Descamps	Bispecific anti-cxcr7 immunoglobulin single variable domains
JP6324887B2 (ja)	2011-06-23	2018-05-16	アブリンクスエン．ヴェー．	血清アルブミンに結合するタンパク質
KR102246924B1 (ko) *	2011-06-23	2021-04-30	아블린쓰 엔.브이.	면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
CN108178800B (zh) *	2011-08-17	2022-06-17	葛兰素集团有限公司	具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
HUE058008T2 (hu)	2014-05-16	2022-06-28	Ablynx Nv	Immunglobulin variábilis domének
NO2768984T3 (no) *	2015-11-12	2018-06-09

2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Application Filing
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 MX MX2018005992A patent/MX2018005992A/es unknown
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active IP Right Grant
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en active Application Filing
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 CA CA3005085A patent/CA3005085A1/en active Pending
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/zh unknown
- 2017-12-15 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
2018
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending

Also Published As

Publication number	Publication date
EP3191511B1 (en)	2017-09-20
KR20180083382A (ko)	2018-07-20
ECSP18042569A (es)	2018-07-31
PH12018501025A1 (en)	2019-01-28
PE20181317A1 (es)	2018-08-14
CR20180311A (es)	2018-10-18
ES2662418T3 (es)	2018-04-06
JP2022020666A (ja)	2022-02-01
PL3191511T3 (pl)	2018-03-30
US20170190769A1 (en)	2017-07-06
BR112018009714A8 (pt)	2019-02-26
JP7357038B2 (ja)	2023-10-05
IL310373A (en)	2024-03-01
KR102641194B1 (ko)	2024-02-26
CN108473563A (zh)	2018-08-31
IL259269A (en)	2018-07-31
CL2018001291A1 (es)	2018-09-14
ME02954B (me)	2018-07-20
AU2016352943A1 (en)	2018-06-07
AU2016352943B2 (en)	2022-10-20
JP2019506839A (ja)	2019-03-14
MA41653A (fr)	2018-01-09
CA3005085A1 (en)	2017-05-18
MX2018005992A (es)	2019-01-31
CO2018005915A2 (es)	2018-06-20
CN108473563B (zh)	2022-06-14
EP3266798A3 (en)	2018-03-28
CY1120303T1 (el)	2019-07-10
RS56676B1 (sr)	2018-03-30
LT3191511T (lt)	2018-01-10
CA3234178A1 (en)	2017-05-18
RU2018120524A3 (no)	2020-09-24
US20170267752A1 (en)	2017-09-21
SG11201803975SA (en)	2018-06-28
US10544211B2 (en)	2020-01-28
JP6962915B2 (ja)	2021-11-10
DK3191511T3 (en)	2018-01-08
KR20240029115A (ko)	2024-03-05
EP3191511A1 (en)	2017-07-19
TN2018000159A1 (en)	2019-10-04
GT201800095A (es)	2019-08-15
HRP20171949T1 (hr)	2018-01-26
RU2018120524A (ru)	2019-12-13
PT3191511T (pt)	2017-11-30
HUE035805T2 (en)	2018-05-28
BR112018009714A2 (pt)	2018-11-21
MD3191511T2 (ro)	2018-03-31
IL259269B1 (en)	2024-03-01
IL259269B2 (en)	2024-07-01
EP3266798A2 (en)	2018-01-10
DOP2018000122A (es)	2018-09-30
US9745372B2 (en)	2017-08-29
WO2017081320A1 (en)	2017-05-18
HK1248716A1 (zh)	2018-10-19
AU2023200113A1 (en)	2023-02-16
SI3191511T1 (en)	2018-01-31

Publication	Publication Date	Title
BR112014017635A2 (no)	2017-06-20
BR112014017625A2 (no)	2017-06-20
BR112014017592A2 (no)	2017-06-20
BR112014017659A2 (no)	2017-06-20
BR112014017646A2 (no)	2017-06-20
BR112014017638A2 (no)	2017-06-20
BR112014017607A2 (no)	2017-06-20
BR112014025880A2 (no)	2017-06-20
BR112013027865A2 (no)	2017-01-03
BR112014017634A2 (no)	2017-06-20
BR112014017609A2 (no)	2017-06-20
BR112014017644A2 (no)	2017-06-20
BR112014017647A2 (no)	2017-06-20
BR112014017588A2 (no)	2017-06-20
BR112014017618A2 (no)	2017-06-20
BR112014013184A8 (no)	2017-06-27
BR112014017630A2 (no)	2017-06-20
BR112014017652A2 (no)	2017-06-20
BR112014017621A2 (no)	2017-06-20
BR112014017622A2 (no)	2017-06-20
BR112014017627A2 (no)	2017-06-20
BR112014017623A2 (no)	2017-06-20
NO2768984T3 (no)	2018-06-09
BR112014017641A2 (no)	2017-06-20
BR112014017631A2 (no)	2017-06-20